M. M. Luk'YAnov

M. M. Luk'YAnov

Auto-generated profile, based on publicly available information

M. M. Luk'YAnov

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ROR. G. Oganov
R. G. Oganov
VSV. I. Simanenkov
V. I. Simanenkov
IBIgor G. Bakulin
Igor G. Bakulin
NBN. V. Bakulina
N. V. Bakulina
OBOlga Barbarash
Olga Barbarash
ЮКЮ. В. Котовская
Ю. В. Котовская
Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения

16 July 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
SBSergey Boytsov
Sergey Boytsov
VOV. V. Omelyanovskiy
V. V. Omelyanovskiy
AKA. V. Kontsevaya
A. V. Kontsevaya
MLM. M. Loukianov
M. M. Loukianov
EDE. V. Derkach
E. V. Derkach
Heart failure (HF) significantly worsens the patient quality of life and leads to the disability of their significant part, as well as increases the risk of death, which in turn causes economic damage.Aim. To assess the annual socio-economic impact of HF in Russia.Material and methods. To assess the socio-economic impact of HF, a model was developed, which assessed the number of HF patients seeking medical care (data from the epidemiological studies), the number of those with disabilities and the mortality rate among them. We also evaluated the costs of drug therapy (data from the government procurement reports) and hospitalization (data from the compulsory health insurance tariffs), social benefits due to disability, and death impact on the gross domestic product. Data on the prescription rate, hospitalizations and mortality was obtained from Russian registries of patients with cardiovascular diseases. Using the foreign study, the costs of family caregiving were also calculated.Results. According to modeling data, there are 7,1 million people with HF seeking medical care in Russia. In this case, the annual economic impact of HF in the context of government spending, is RUB 81,86 billion, including medical costs of RUB 18,6 billion, direct nonmedical costs of RUB 47,1 billion, and indirect costs of RUB 16,2 billion. The impact of family caregiving is RUB 72,4 billion. In the structure of medical expenses, 73,6% is hospitalization costs, while the main costs of drug therapy are borne by patients, since only a part of them (19,6%) receive the necessary medications within assistance programs. In patients with HF with reduced ejection fraction, medical costs are 56% higher than in patients with HF with preserved ejection fraction.Conclusion. HF causes significant economic burden to the state. Improving the healthcare system for this category of patients, including preferential drug provision, will reduce HF-related mortality, the healthcare system costs and, accordingly, reduce the economic impact on the state and society.

1 April 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
AKA. V. Kontsevaya
A. V. Kontsevaya
AKA. M. Kalinina
A. M. Kalinina
SASergey Avdeev
Sergey Avdeev
MAM. V. Agaltsov
M. V. Agaltsov
БДБ. Ю. Джонова
Б. Ю. Джонова
Создание руководства поддержано Советом по терапевтическим наукам отделения клинической медицины Российской академии наук.

1 January 2014 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
MLM. M. Loukianov
M. M. Loukianov
SBS. A. Boytsov
S. A. Boytsov
SYS. S. Yakushin
S. S. Yakushin
SMS. Yu. Martsevich
S. Yu. Martsevich
AVArray N. Vorobyev
Array N. Vorobyev
EKE. N. Kudryashov
E. N. Kudryashov
DIAGNOSTICS, TREATMENT, ASSOCIATED CARDIOVASCULAR AND CONCOMITANT NON-CARDIAC DISEASES IN PATIENTS WITH DIAGNOSIS OF “ATRIAL FIBRILLATION” IN REAL OUTPATIENT PRACTICE (ACCORDING TO DATA OF REGISTRY OF CARDIOVASCULAR DISEASES, RECVASA)

15 August 2022 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
AKA. V. Kontsevaya
A. V. Kontsevaya
DMD. K. Mukaneeva
D. K. Mukaneeva
MSM. I. Smirnova
M. I. Smirnova
AAA. A. Antsiferova
A. A. Antsiferova
SASergey Avdeev
Sergey Avdeev
Chronic obstructive pulmonary disease (COPD) is characterized by a high level of morbidity and mortality and is associated with significant social and economic losses for the health care system and society.Aim. To predict the socio-economic burden of COPD in the Russian Federation in 2022, including the cost of drug treatment.Methods. The socio-economic burden of COPD in the Russian Federation in 2022 was predicted with and without taking into account the impact of COVID-19. The analysis of the cost of illness included the calculation of direct and indirect costs due to COPD. Data of Federal State Statistics Service, the State Guarantee Program of Free Medical Care for Citizens of Russian Federation, and data from the regional register of drug treatment of patients with COPD were used. Costs of medical care (ambulatory, hospital, and emergency care) were calculated based on compulsory health insurance tariffs. The disability benefits payments were calculated based on number of disabled persons and the amount of the disability benefit in each group. Indirect costs (or economic losses) included losses from products which were not produced due to disability and premature mortality of working-aged adults.Results. The predicted total economic losses due to COPD in 2022 will be 428.5 billion rubles when taking into account the impact of COVID-19, and 378.9 billion rubles when not accounting for COVID-19. Losses in the economy due to decreased labor productivity because of premature deaths (86%) are major part of the main burden. The cost of drug therapy for patients with COPD in outpatient settings will amount to over 17 billion rubles.Conclusion. Potential economic burden of COPD in 2022 depends on the incidence of COVID-19 and could be 0.34% of the GDP. Priority should be given to measures aimed at preventing the occurrence of COPD by correcting risk factors in the population, early diagnosis, slowing the progression of the disease and preventing exacerbations. Prevention of respiratory infections including COVID-19 in patients with COPD plays a special role.

1 October 2015 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
IKIgor Kolos
Igor Kolos
ATAlexandr Troitskiy
Alexandr Troitskiy
TBTatiana Balakhonova
Tatiana Balakhonova
MSMerab Shariya
Merab Shariya
DSDenis Skrypnik
Denis Skrypnik
NUNataliya V. Ust'YAntseva
Nataliya V. Ust'YAntseva